Valuation
- Market cap
- 915,074,000
- Revenue TTM
- $568,090,000
- Net income TTM
- $22,730,000
- P/E (trailing)
- 14.09
- P/E (forward)
- 14.09
- Profit margin
- 4.00%
- Debt to equity
- 0.79
Trading
- Volume
- 650,600
- Avg volume
- 528,246
- Day's range
- $10.64 – $11.00
- Shares out
- 84,261,000
- Stochastic %K
- 31%
- Beta
- 0.66
- Analysts
- Strong Buy
- Price target
- $17.00
Company profile
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to t...
Show more
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
- Industry
- Medical Devices
- Sector
- Healthcare
- Phone
- 919 474 6700
- Website
- https://www.bioventus.com
- Address
- 4721 Emperor Boulevard, Suite 100, Durham, United States
Latest news
No headlines yet.
Stocktwits
Danielord
Nov 3, 3:16 PM
$BVS i opened short position what about u guys?
1 replies
GTA_Terminal
Nov 3, 4:08 AM
Dark pool volume in
$BVS ran above normal, about 1.3x its usual pace. The full read shows the session-by-session dark pool share and which institutions are adding or cutting.
The full dark-pool read, with the options side:
https://globaltradersacademy.com/articles/dark-pool-activity-what-big-money-did-in-bioventus-bvs-off-the-exchanges?utm_source=stocktwits&utm_medium=social
0 replies
Mike22332233
Nov 3, 1:36 AM
$BVS
This lowering of expected revenues for 2026 was telegraphed yesterday with a big down move from the
$14.85 close the day before ... and today down to
$10.50 in AH ....
A stunning 29.3% decline in market cap !!!!
And why? ... because they lowered revenue expectations by 3.2% !!!!
STUNNING and time to buy more!!! Good chance for BO offer of
$18.50 to
$20 to be announced VERY VERY SOON !!!
LIKE & FOLLOW @Mike22332233
0 replies
notreload_ai
Nov 2, 10:39 PM
AH drops:
$BVS ~10% down—sales +3% to
$142M missed, cut FY revenue forecast (profit ok, weak growth outlook).
$TVTX ~4% down: FILSPARI
$200M (+120%), but
$113M one-time charge bigger loss.
$BMRN ~6% down: sales >
$1B (+32%), cut 2026 rev & EPS on order timing + costly deals. https://notreload.xyz/wall-street-live-monday-november-2/
0 replies
shoc24
Nov 2, 10:29 PM
$BVS reported earnings today after the close and beat EPS estimates:
$0.17 adjusted EPS vs
$0.1496 expected, according to Stock Meadow.
0 replies
EarningsInsider
Nov 2, 10:16 PM
https://www.marketbeat.com/earnings/reports/2026-11-2-bioventus-inc-stock-1/
$BVS Bioventus Earnings Transcript
0 replies
Regenerative2025
Nov 2, 10:04 PM
$BVS Pathetic result for the quarter and lowering guidance.Lots of excuses and no willingness to discuss the strategic review which they had no business discussing last quarter.Today the group really lost their credibility!
0 replies
StocktwitsEarnings
Nov 2, 9:18 PM
$BVS Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of
$0.17 up 13.33% YoY
• Reported revenue of
$142.44M up 2.73% YoY
• Bioventus reaffirmed FY2026 Adjusted EPS guidance of
$0.75 to
$0.79 per diluted share, with net sales guidance of
$590M to
$595M and Adjusted Cash from Operations of
$84M to
$89M.
0 replies